170632-13-0

Basic information

• Product Name: 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester
• CAS NO: 170632-13-0
• Molecular Formula: C20H16N2O3
• Molecular Weight: 332.359
• Mol File: 170632-13-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester(170632-13-0)
• EPA Substance Registry System: 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester(170632-13-0)

Safety Data

• Hazardous Substances Data: 170632-13-0(Hazardous Substances Data)

Usage

Description

2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester is a chemical compound that belongs to the class of furancarboxylic acid esters. It is a methyl ester derivative of 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furancarboxylic acid, which has been used in medicinal chemistry research as a potential drug candidate. 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl
ester's structure contains a furan ring and an indazole ring, which are both aromatic heterocycles. This chemical may have biological activities or pharmacological properties, although further research is needed to fully understand its potential uses and effects.

Uses

Used in Medicinal Chemistry Research:
2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester is used as a potential drug candidate in medicinal chemistry research for its possible biological activities and pharmacological properties. Its unique structure with a furan ring and an indazole ring may contribute to its potential therapeutic applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Furancarboxylic acid, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-, methyl ester is used as a chemical intermediate for the synthesis of various drug molecules. Its aromatic heterocycles may provide a structural basis for the development of new drugs with improved efficacy and safety profiles.

Upstream product

• 2527-99-3 methyl 5-bromo-2-furoate 
• 215789-59-6 Trifluoro-methanesulfonic acid 1-benzyl-1H-indazol-3-yl ester 
• 353504-67-3 5-(2-amino-benzoyl)-furan-2-carboxylic acid methyl ester 
• 353504-65-1 5-(2-nitro-benzoyl)-furan-2-carboxylic acid methyl ester 
• 67-56-1 methanol 
• 170632-42-5 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole 
• 43120-25-8 1-benzyl-1H-indazole 
• 271-44-3 benzimidazole 
• 205643-28-3 N-benzyl-3-iodo-1H-indazole 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 377739-88-3 5-methoxycarbonylfuryl phenyl ketone benzylhydrazone 
• 100-44-7 benzyl chloride 
• 7364-25-2 3-indazolinone 
• 2215-63-6 1-benzyl-1,2-dihydro-3H-indazol-3-one 

Downstream Products

• 170632-42-5 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole 
• 170632-47-0 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole 

Relevant articles and documents

Novel Pyrazole Derivatives Effectively Inhibit Osteoclastogenesis, a Potential Target for Treating Osteoporosis

As human beings live longer, age-related diseases such as osteoporosis will become more prevalent. Intolerant side effects and poor responses to current treatments are observed. Therefore, novel effective therapeutic agents are greatly needed. Here, pyrazole derivatives were designed and synthesized, and their osteoclastogenesis inhibitory effects both in vitro and in vivo were evaluated. The most promising compound 13 with a 2-(dimethylamino)ethyl group inhibited markedly in vitro osteoclastogenesis as well as the bone resorption activity of osteoclasts. Compound 13 affected osteoclasts early proliferation and differentiation more than later fusion and maturation stages. In ovariectomized (OVX) mice, compound 13 can inhibit the loss of trabecular bone volume, trabecular bone number, and trabecular thickness. Moreover, compound 13 can antagonize OVX-induced reduction of serum bone resorption marker and then compensatory increase of the bone formation marker. To sum up, compound 13 has high potential to be developed into a novel therapeutic agent for treating osteoporosis in the future.

Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors

Design, synthesis and insight into the structure-activity relationship (SAR) of 1,3-disubstituted indazoles as novel HIF-1 inhibitors are described. In particular, the substituted furan moiety on indazole skeleton as well as its substitution pattern turns

Preparation of highly functionalized heterocyclic zinc organometallics via a Li(acac)-catalysis of the I/Zn-exchange reaction

The reaction of i-Pr2Zn in the presence of catalytic amount of Li(acac) in NMP with various functionalized heterocyclic iodides provides new polyfunctional diheteroarylzincs, which undergo smooth Negishi cross-coupling reactions and CuCN-2LiCl-